Intelligent Bio Solutions Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.2%projected annual EPS growth
Analyst Coverage
1analyst covering
FY Revenue (est.)
$4.3Mnext fiscal year
FY EPS (est.)
-$3.42next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q1 Fiscal 2027 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly1.1MTarget: Continued double-digit year-over-year growth
Gross Profit Margin Quarterly5,047.0%Target: Maintain above 50%
Cartridge Sales Revenue Quarterly703.5KTarget: Expansion of recurring consumable sales mix
Cash and Cash Equivalents Quarterly6.9MTarget: Sufficient runway to fund FDA 510(k) submission and clinical trials
Watch Items
- FDA 510(k) Submission ProgressTrigger: Completion of clinical studies (Interference and Method Comparison) by mid-to-late July 2026Action: Compile and submit the final 510(k) package to the FDA for U.S. market clearance of the Intelligent Fingerprinting Drug Screening System.
- U.S. Market Entry TimelineTrigger: FDA clearance decisionAction: Initiate commercial launch and scale up sales and marketing operations in the United States.
- Cash Burn Rate and Capital RunwayTrigger: Cash reserves dropping below $3.0 millionAction: Evaluate additional non-dilutive or dilutive capital raising options to sustain operations prior to commercialization in the U.S.
Research as of 20 Jun 2026